These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 10678360

  • 1. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
    Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ, Kurimoto M, Gohji K, Arakawa S, Ichihashi M, Kamidono S.
    Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H, Matsumoto A, Kitamura T, Takeuchi T.
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG, Younes E, Visscher D, Hamzavi F, Kim S, Lam JS, Montecillo EJ, Ali E, Pontes JE, Puri RK, Haas GP.
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [Abstract] [Full Text] [Related]

  • 7. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
    Kasaoka Y, Nakamoto T, Wang J, Usui T, Hamada H.
    Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Cancer Res; 2001 Oct 15; 61(20):7563-7. PubMed ID: 11606395
    [Abstract] [Full Text] [Related]

  • 10. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ, Kazimierczak U, Suchorska W, Kotlarski M, Malicki J, Mackiewicz A.
    Cancer Gene Ther; 2010 Jul 15; 17(7):465-75. PubMed ID: 20168352
    [Abstract] [Full Text] [Related]

  • 11. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [Abstract] [Full Text] [Related]

  • 12. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
    Mendiratta SK, Quezada A, Matar M, Wang J, Hebel HL, Long S, Nordstrom JL, Pericle F.
    Gene Ther; 1999 May 01; 6(5):833-9. PubMed ID: 10505108
    [Abstract] [Full Text] [Related]

  • 13. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS, Cho WK, Yoo J, Seong YR, Kim BK, Kim S, Im DS.
    Cancer Gene Ther; 2004 Jun 01; 11(6):397-407. PubMed ID: 15044962
    [Abstract] [Full Text] [Related]

  • 14. Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.
    Taniguchi F, Yamagishi H, Fujiwara H, Ueda Y, Fuji N, Yoshimura T, Oka T.
    Gene Ther; 1998 Dec 01; 5(12):1677-84. PubMed ID: 10023447
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T, Konno-Takahashi N, Kasuya Y, Ogushi T, Nishimatsu H, Kitamura T.
    BJU Int; 2004 Jul 01; 94(1):171-6. PubMed ID: 15217455
    [Abstract] [Full Text] [Related]

  • 16. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model.
    Hikosaka S, Hara I, Miyake H, Hara S, Kamidono S.
    Int J Urol; 2004 Aug 01; 11(8):647-52. PubMed ID: 15285756
    [Abstract] [Full Text] [Related]

  • 17. T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus.
    Siders WM, Wright PW, Hixon JA, Alvord WG, Back TC, Wiltrout RH, Fenton RG.
    J Immunol; 1998 Jun 01; 160(11):5465-74. PubMed ID: 9605149
    [Abstract] [Full Text] [Related]

  • 18. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
    Saffran DC, Horton HM, Yankauckas MA, Anderson D, Barnhart KM, Abai AM, Hobart P, Manthorpe M, Norman JA, Parker SE.
    Cancer Gene Ther; 1998 Jun 01; 5(5):321-30. PubMed ID: 9824052
    [Abstract] [Full Text] [Related]

  • 19. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M, Nishigori C, Ichihashi M.
    Exp Dermatol; 2004 Oct 01; 13(10):613-20. PubMed ID: 15447721
    [Abstract] [Full Text] [Related]

  • 20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 01; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.